## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.0% in lower entry zone (3.0-6.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (2.1%) confirms momentum alignment. Strong momentum (+1.8% 5-day acceleration). Outperforming sector by 3.2%. Caution: overbought RSI (70).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($26.28)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 12-Month Share Price Rally**
- Source: Simply Wall Street | 20251221T210959 | Somewhat-Bullish | Relevance: 100%
- ACADIA Pharmaceuticals (ACAD) has seen significant growth in its share price over the past year, up 61%, and is currently trading just below consensus price targets. Despite this rally, a detailed long-term cash flow analysis suggests the stock might be modestly undervalued, with a narrative fair value of $29.32 against a current price of $27.16. The valuation hinges on assumptions of durable double-digit growth and steady margins, and investors should consider potential risks like NUPLAZIDâ€™s concentration risk or setbacks in late-stage trials.

**2. Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com**
- Source: Investing.com Canada | 20251222T160959 | Bullish | Relevance: 100%
- Acadia Pharmaceuticals stock has reached a 52-week high of $27.73, reflecting a 61% increase over the past year and strong investor confidence. The company maintains a "GREAT" financial health score and its stock appears undervalued at its current price. Recent FDA approval for DAYBUE STIX and varied analyst price target adjustments further contribute to a positive outlook for the biopharmaceutical firm.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | HC Wainwright & | $37 | $32 | +16% |
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | HC Wainwright & | main | Buy |
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- Momentum building: MRS_10 improving +1.8% over 5 days suggests accumulation.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (3 raises, avg +14%). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.67 |
| 52W Range | $13.40 - $28.26 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 34.8 |
| Current P/E | 34.4 |
| YoY Growth | -1.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.3% to 3.0% (+1.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 89th percentile. MRS_5 at 2.1% confirms short-term momentum alignment. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 70, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.04% (CS: 90) | Strong |
| RSI_14 | 70.4 | Overbought |
| MACD Histogram | -0.00 | Bearish |
| vs SMA20 | 1.068x | Above |
| vs SMA50 | 1.173x | Above |
| vs SMA200 | 1.304x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $28.06
- **Stop Loss:** $26.28 (6.3% risk)
- **Target:** $30.73 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 674
- **Position Value:** $18,912.44
- **Portfolio %:** 18.91%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*